Categorynews

Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting

April 1, 2019 Off By BusinessWire

NEW YORK–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biotech?src=hash" target="_blank"gt;#biotechlt;/agt;–Rgenix, Inc., a clinical stage biopharmaceutical company developing
first-in-class small molecule and antibody cancer therapeutics,
announced today that Isabel Kurth, Ph.D., Vice President of Research at
Rgenix, will present an abstract about Rgenix’s RGX-019 program at the
2019 American Association for Cancer Research Annual Meeting. The
meeting is scheduled to take place Friday, March 29 through Wednesday,
April 3 in Atlanta.

The details of Rgenix’s presentation are as follows:


Event:				AACR Annual Meeting 2019

Date:				April 3, 2019

Time:				8:00 A.M. – 12:00 P.M. EST

Description:				Abstract LB-277/23, “Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor”

Location:				Section 40, Georgia World Congress Center, 285 Andrew Young International Blvd
				NW, Atlanta, GA 30313

Dr. Kurth will present data from pre-clinical research of RGX-019, a
novel pre-clinical stage humanized monoclonal antibody targeting the
MERTK receptor.

About Rgenix

Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical
company focused on the discovery and development of novel cancer drugs
that target key pathways in cancer progression. The company is pursuing
several first-in-class drug candidates to treat cancers of high unmet
need. Rgenix identifies novel cancer targets using a microRNA based
target discovery platform originally developed by Rgenix’s scientific
co-founders at The Rockefeller University and now exclusively licensed
to Rgenix. The company brings together distinguished scientific
founders, a seasoned Board, and a leadership team comprised of
experienced drug developers. The company is funded by leading
biotechnology investors, including Novo Holdings A/S, Sofinnova
Partners, Lepu Holdings Limited, Oceanpine Capital, WuXi PharmaTech
Healthcare Fund I, LP, Alexandria Venture Investments,LLC, and the
Partnership Fund for New York City. For more information, please visit www.rgenix.com.

About RGX-019

RGX-019 is an investigational drug candidate and a humanized
monoclonal antibody that targets MERTK being developed by Rgenix for the
treatment of advanced cancer. Rgenix in-licensed RGX-019 related
antibody intellectual property from Rockefeller University as part of a
world-wide exclusive licensing agreement.

MERTK is a receptor tyrosine kinase of the TAM family and is
over-expressed in several human cancers. The MERTK pathway drives cancer
progression, tumor angiogenesis, and innate immune suppression.
Targeting MERTK inhibits the growth of MERTK-expressing cancer cells and
induces an M1 pro-inflammatory cytokine expression profile in
tumor-associated macrophages. Rgenix has initiated IND-enabling studies
of RGX-019.